Fuse Medical (OTCMKTS:FZMD) Vs. ELDN, ECOR, MYO, FOXW, SNPX, EYES, COCP, BPTS, BMRA, and CYCN
Should you be buying Fuse Medical stock or one of its competitors? The main competitors of Fuse Medical include Eledon Pharmaceuticals (ELDN), electroCore (ECOR), Myomo (MYO), FoxWayne Enterprises Acquisition (FOXW), Synaptogenix (SNPX), Second Sight Medical Products (EYES), Cocrystal Pharma (COCP), Biophytis (BPTS), Biomerica (BMRA), and Cyclerion Therapeutics (CYCN). These companies are all part of the "medical & hospital equipment" industry.These companies are all part of the "medical & hospital equipment" industry.These companies are all part of the "medical" sector.
Fuse Medical vs.
Fuse Medical (OTCMKTS:FZMD) and electroCore (NASDAQ:ECOR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, community ranking, institutional ownership, risk, profitability, media sentiment, valuation, analyst recommendations and earnings.
Fuse Medical has higher revenue and earnings than electroCore. Fuse Medical is trading at a lower price-to-earnings ratio than electroCore, indicating that it is currently the more affordable of the two stocks.
In the previous week, electroCore had 8 more articles in the media than Fuse Medical. MarketBeat recorded 9 mentions for electroCore and 1 mentions for Fuse Medical. electroCore's average media sentiment score of 0.14 beat Fuse Medical's score of 0.00 indicating that electroCore is being referred to more favorably in the news media.
electroCore received 103 more outperform votes than Fuse Medical when rated by MarketBeat users. However, 66.67% of users gave Fuse Medical an outperform vote while only 60.71% of users gave electroCore an outperform vote.
Fuse Medical has a net margin of -4.88% compared to electroCore's net margin of -380.36%. Fuse Medical's return on equity of 0.00% beat electroCore's return on equity.
20.0% of electroCore shares are owned by institutional investors. 92.9% of Fuse Medical shares are owned by company insiders. Comparatively, 13.8% of electroCore shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
electroCore has a consensus price target of $2.31, indicating a potential upside of 180.27%. Given electroCore's higher probable upside, analysts plainly believe electroCore is more favorable than Fuse Medical.
Summary
Fuse Medical and electroCore tied by winning 8 of the 16 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding FZMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of OTCMKTS and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment >-1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fuse Medical (OTCMKTS:FZMD) vs. Its Competitors
Fuse Medical Competitors List
